A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Sponsor: Kahr Medical
Terminated
Slow enrolment
This PHASE1 trial investigates Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia and is currently terminated or withdrawn. Kahr Medical leads this study, which shows 11 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Nov 2024 — Jun 2025 [monthly]
Recruiting PHASE1
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Apr 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Dec 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Mar 2022 — Dec 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kahr Medical
For direct contact, visit the study record on ClinicalTrials.gov .